C7A.8 — Other malignant neuroendocrine tumors
C7A.8 is a billable, specific ICD-10-CM code for other malignant neuroendocrine tumors. It is valid for submission on a claim.
Risk adjustment
C7A.8 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 21 Lymphoma and Other Cancers0.671 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C7A.8 is named in 67 Medicare coverage policies — 67 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
How C7A.8 is indexed
Coders do not find codes by browsing the tabular list — they look them up in the alphabetic index, under the word the physician wrote. These are the index entries that lead here, so you can see which chart wordings map to C7A.8.
- Tumor›neuroendocrine›specified NEC
Related codes at this level
Codes that share C7A. If C7A.8 is not quite right, the correct code is usually one of these.
Questions about C7A.8
- Is C7A.8 a billable ICD-10-CM code?
- Yes. C7A.8 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C7A.8 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neuroendocrine tumors (C7A).